Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
2025-520821-19-00Phase 2Authorised
- Sponsor
- AFT Pharmaceuticals
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in port-wine stain (4 arms), sponsored by AFT Pharmaceuticals. Primary endpoint: Change in PWS colour extent and intensity at week 12. Planned start Jan 2025; status: authorised.
02
Drugs
sirolimus
03
Conditions
port-wine stain
Beyond the preview
Go deeper on 2025-520821-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520821-19-00.